HeadInvest LLC’s AstraZeneca AZN Stock Holding History

HeadInvest LLC’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-350	Closed	-$46.7K	–	265
2023 Q3	$46.7K	Buy	+350	New	+$47.8K	0.01%	357

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HeadInvest LLC's AZN Position: Q4 2023 in Review

HeadInvest LLC sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 350 shares — an estimated $46.7K sold.

HeadInvest LLC first reported a position in AZN in Q3 2023 and held it in 1 quarter. The position peaked at $46.7K in Q3 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

HeadInvest LLC reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 350 AstraZeneca shares in Q4 2023, an estimated $46.7K.
HeadInvest LLC first reported a position in AstraZeneca in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's AstraZeneca position peaked at $46.7K in Q3 2023.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.